Time to Buy Pfizer Shares

Shares of Pfizer Inc. (NYSE:PFE) have flattened out a bit over the past two weeks, leaving the current trading price close to the 20-day moving average stock price.  This may prove to be a great time to invest in shares of the company as share price may bounce off the 20-day moving average to continue its uptrend.

WallStNation.com Sponsors - Become one Today

Right now, the average of analysts has projected earnings to be at $0.46/share, with the top range being $0.49/share and the lower being $0.43/share.  The $0.46/share estimate is down slightly (-6.35%) from the year ago EPS which was $0.49/share.

The company has strong sales as the last quarter versus year ago quarter is up a healthy 39.2%, beating out its industry’s average of 18.8%.  The company’s current P/E ratio of 24.1 is above its industry peers’ average of 15.0.

Over the past 12 months Pfizer Inc (PFE) shares have traded between a 52-week low of $14.00 and its 52-week high of $19.33.  PFE shares are trading at $18.40, up 0.19% or $0.04 on the day and getting closer to that 52-week high.

Another reason to consider Pfizer, Vitaliy Katsenelson likes it, he's the author behind two great books   the Little Book of Sideways Markets (Wiley, 2010) and Active Value Investing (Wiley, 2007).

Vitaliy Katsenelson on Pfizer
(http://www.minyanville.com | Jan 26th) By way of example, what follows are a few companies that I consider to be highest-quality, and I own these stocks in our accounts. The first two are in health care. Though the uncertainty that ObamaCare brought is behind us and its impact on the industry will be relatively small, health-care stocks did not get the message. Pfizer (PFE), the largest pharmaceutical company in the world, is trading at less than eight times earnings. It is generating enormous cash flows, pays a 4.5% dividend (which it just raised), and will be debt-free in the not-too-distant future. Yet the market puts zero value on its enormous pipeline of drugs in development and the $10 billion Pfizer spends annually on R&D.

ABOUT PFE
Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment offers products in the areas of primary care, specialty care, established products, emerging markets, and oncology customer-focused units.